sameAs
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesDevelopment of a new vaccine for the prevention of Lassa fever.Clinical management of filovirus-infected patientsProposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviationsThe NIAID Integrated Research Facility at Frederick, Maryland: a unique international resource to facilitate medical countermeasure development for BSL-4 pathogensMiddle East respiratory syndrome: obstacles and prospects for vaccine developmentModeling [(18)F]-FDG lymphoid tissue kinetics to characterize nonhuman primate immune response to Middle East respiratory syndrome-coronavirus aerosol challenge.Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccineGenomic Characterization of the Genus Nairovirus (Family Bunyaviridae)Panmicrobial Oligonucleotide Array for Diagnosis of Infectious DiseasesCrimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapiesReduced evolutionary rate in reemerged Ebola virus transmission chainsNeglected filovirusesEvaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T CellsThe effect of volume of interest definition on quantification of lymph node immune response to a monkeypox virus infection assessed by (18)F-FDG-PET.Clarification and guidance on the proper usage of virus and virus species namesImmune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPsSafety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 1. Biosafety Level 4 Suit Laboratory Suite Entry and Exit ProceduresAnimal Models of Ebolavirus Infection.ABSL-4 aerobiology biosafety and technology at the NIH/NIAID integrated research facility at Fort DetrickEssentials of filoviral load quantification.The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionRepurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.Nyamiviridae: proposal for a new family in the order MononegaviralesDetection and identification of Variola virus in fixed human tissue after prolonged archival storage.Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay.Cynomolgus macaque as an animal model for severe acute respiratory syndrome.Neutralizing antibody fails to impact the course of Ebola virus infection in monkeysExploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNALoss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus.Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus SpeciesHigh dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona.Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event.Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.Progression of pathogenic events in cynomolgus macaques infected with variola virusEbola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes.Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates
P50
Q21131585-1F8CE443-EF7F-4B8E-888F-1C83CFB954C9Q21563440-6916403C-7F4A-40AF-AB70-D73D922AFA10Q22305518-C724677D-6B2B-45E5-AF44-879BFA437C36Q24620453-18C59603-5BB4-43C7-9C1D-0C38F6D272C9Q26823815-313ACBEF-D310-47CF-8809-75DC914A07FCQ27013314-B09FB216-743A-4659-94E9-D3198A73AFE7Q27321197-CFF9E6A9-F4B2-42E3-8B80-96D6FEFDBD78Q27334697-AB4CFF54-10D7-4207-A53D-861F62B88357Q27469076-8D3C06DB-FEC8-4E10-B571-04F7E5D2BB44Q27489133-D56616B0-3101-4381-A17F-906DE4B3561DQ28306281-F5519C64-805A-4D23-915C-BE217DFBE34FQ28383109-E83222EE-29FF-4BFE-89F1-5EB60E7277F6Q28383265-1A33D6B4-79AA-4E69-839A-EE09F5E4DC63Q28554599-5947084F-8E85-49A3-8E80-7BEF22B0F3C2Q28602577-8F377A9D-8802-44D1-B6F1-E542E20619A9Q28646230-1E10F268-4861-4575-BF40-BE4E9CE06768Q28751879-09A48A40-943F-4C18-A48A-9C1E98919B2FQ28768041-6FDE7885-B85C-408D-A93B-D82D5777F365Q28822312-C20BF5B6-14DE-424E-8FB3-E65F8D38DAB4Q30148647-6A1B1BC8-4B9C-4E2B-82BB-232775E180BEQ30217454-562B3DD9-6211-4B4D-B893-585FEA45C9B0Q30249651-C75B64C3-80A4-4CAC-AFE7-0FC266DFCC1AQ30252649-FA2833E9-FAC7-4952-840C-D27E8439A81AQ30419612-CE434A08-A0DE-4DE5-900A-5AC1B9CEB807Q30620785-190169A3-0365-4426-BC1B-24049876FF70Q31027770-073B0B54-0ECD-4DE7-835E-6269089D0E6DQ31112631-ED565709-5A1D-4003-BB70-0299C8D3A16BQ33239453-6E8A092A-9DF7-4CDD-9289-F933C7C51107Q33269796-D85D45F7-A3C3-4C0B-AB37-C1831C7F47F8Q33363190-2452E053-DA5E-410F-BE83-3095A83A95FAQ33568288-C2F43E9A-6304-4847-8721-FF102060754FQ33579992-CF2551E5-F239-4E8B-952A-E664684291F6Q33587515-35713C56-8687-4648-9F4A-AAF146105C48Q33919019-48E31449-CEF9-4813-8FEB-F7C69BC5B50CQ33974171-A18186FC-6CA1-4A7A-83B7-5BD279E7A90AQ33974706-67203AC2-F98B-4BB7-A467-1BC898F62A62Q33987611-14FF330D-3355-4636-AEC0-AAA99EB005D0Q34048130-3CAA6FD8-DB49-40FF-8A11-1D2DCA7008ECQ34059380-A1762C81-0580-4F54-B24B-4AA10F426C80Q34120895-A8705FCE-DD5B-4CA2-A4CF-ADE82D27BE27
P50
description
hulumtues
@sq
investigador
@es
researcher
@en
viroloog
@nl
name
Peter B. Jahrling
@en
Peter Jahrling
@ast
Peter Jahrling
@es
Peter Jahrling
@nl
type
label
Peter B. Jahrling
@en
Peter Jahrling
@ast
Peter Jahrling
@es
Peter Jahrling
@nl
altLabel
Jahrling P
@en
Jahrling P. B.
@en
Jahrling P.
@en
Jahrling PB
@en
Jahrling
@en
P B Jahrling
@en
P Jahrling
@en
P. B. Jahrling
@en
P. Jahrling
@en
Peter B Jahrling
@en
prefLabel
Peter B. Jahrling
@en
Peter Jahrling
@ast
Peter Jahrling
@es
Peter Jahrling
@nl
P106
P21
P31
P496
0000-0002-9775-3724